ABSTRACT Objectives To establish the role and effect of glucocorticoids and the endogenous annexin A1 (AnxA1) pathway in inß ammatory arthritis.
INTRODUCTION
There is genuine interest in detailing cellular and molecular events regulating the phase of the resolution of infl ammation, with the characterisation of specifi c players and targets. 1 This interest stems from the appreciation that, in ideal settings, a strong pro-infl ammatory response, orchestrated by cytokines, adhesion molecules and chemoattractants 2 must be followed by an anti-infl ammatory and pro-resolving phase, which assures spatial and timely control of the response the host organises upon encounter with an insult, 3 leading to resolution and regain of tissue functions.
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Annexin A1 (AnxA1) is an effector of resolution. 4 Highly expressed in immune cells (eg, polymorphonuclear cells and macrophages), this protein is externalised to exert paracrine and juxtacrine effects, the vast majority of which are mediated by the formylpeptide receptor type 2 (FPR2/ALX ([Lipoxin A4 receptor]) or FPR2, in rodents). 5 Intriguingly, FPR2/ ALX is also the lipoxin A 4 receptor 6 indicating the existence of important -yet not fully appreciated -networks in resolution. 7 Another receptor is also advocated to mediate the effects of AnxA1, the formyl-peptide receptor type 1 or FPR1 (FPR1 in rodents), 8 though it is unclear if and how this receptor binds the full-length protein 9 or whether -more selectively -it would mediate effects of the AnxA1 peptidomimetic peptide Ac2-26. 10 The majority of experimental approaches used to defi ne properties of pro-resolving mediators have been reliant on models of acute infl ammation, characterised by rapid polymorphonuclear infl ux followed by infl ammatory monocytes which differentiate into tissue macrophages 3 11 to phagocytose debris and apoptotic cells and favour tissue repair, a conclusive act in resolution that may require reepitheliation 12 or a shift in fi broblast phenotype. 13 In this context, the pro-resolving nature of AnxA1 has been demonstrated in a variety of experimental settings, noting induction of apoptosis, promotion of efferocytosis and tissue repair, spanning from models of acute infl ammation (eg, 14 15 ) to a model of colitis where delayed resolution was observed in AnxA1 −/− mice. 16 An important aspect of AnxA1 biology is its second messenger role in the actions of glucocorticoids, a function mainly addressed in cellular settings (eg, 17 ) or in models of acute infl ammation. 18 19 However, Yang's group applied antigen-induced arthritis to observe reduction afforded by dexamethasone (Dex) on synovitis, soft tissue infl ammation and cartilage erosion attenuated in AnxA1 −/− mice. 20 The K/BxN serum-induced model of infl ammatory arthritis is ideal for investigating the impact of specifi c pro-resolving pathways. Using this model of active phase of rheumatoid arthritis, Krönke et al reported a higher degree of joint infl ammation in 12/15-lipoxygenase −/− mice, associated with their inability to synthesise lipoxin A 4 . 21 Similarly, animals nullifi ed for pro-resolving melanocortin receptor type 3 displayed higher degree of arthritis and delayed resolution, accompanied by augmented cytokine expression and osteoclast responsiveness. 22 An equally interesting study investigated the effect of absence of glucocorticoid signal in osteoblasts, by means of restricted transgenic expression of 11β-hydroxysteroid dehydrogenase type 2, in this model of infl ammatory arthritis. The outcome was that of a more attenuated arthritis in the transgenic mice when assessed macroscopically and histologically, and selectively in the delayed phase, after peak disease. 23 The present study made use of the serum-induced model of infl ammatory arthritis to: (1) monitor potential modulation of endogenous AnxA1, FPR1 and FPR2; (2) determine the effect of Dex in wild type and AnxA1 −/− mice; and (3) establish the pharmacological potential of exogenously administered AnxA1.
MATERIALS AND METHODS Animals
BALB/c male 8-week old wild type AnxA1 +/+ and AnxA1 −/− mice 24 were bred at Charles River (Kent, UK). All experiments were approved and performed under the guidelines of the Ethical Committee for the Use of Animals, Barts and The London School of Medicine and Home Offi ce regulations (Scientifi c Procedures Act, 1986).
Model of inß ammatory arthritis Arthritis induction
Mice received either 50+50 μl (day 0 and 2) or 200 μl (day 0) of arthritogenic K/BxN serum. 22 Disease was monitored by assessing the clinical score where a maximum of 12 points could be given per animal: 0 point, no evidence of infl ammation; 1 point, subtle infl ammation on metatarsal phalanges joints, individual phalanx; 2 points, swelling on dorsal or ventral surface of paw; 3 points, major swelling on all aspects of paw. 25 Paw volume was assessed by water plethysmometry (Ugo Basile, Milan, Italy).
Pharmacological intervention
Mice were injected intraperitoneally with Dex (disodium salt; Sigma, Dorset, UK) prepared in sterile phosphate buffered saline (Sigma) and given at a dose range of 3-30 μg once daily after disease onset (from day 2). AnxA1 and SuperAnxA1 were generated as recently described 26 and administered intraperitoneally, from day 2, at 1 μg per mouse. 26 
Histology and immunohistochemistry Histology
Joints were decalcifi ed and paraffi n embedded. Sections (4 micrometers) were stained with H&E or safraninO with fast green counterstain. Standard light microscopy was used to determine the degree of synovitis, pannus formation, cartilage and bone erosion which were graded from 0 (no disease) to 5 (severe) by two blinded examiners, as reported. 22 
Immunohistochemistry
An antigen retrieval step using citrate buffer (pH 6.0) was performed and then sections were incubated with rabbit polyclonal anti-AnxA1 (1:1000) (Zymed Laboratories, Cambridge, UK) or anti-FPR2 (1:4000). 27 After washing and the secondary biotinylated antibody (Dako, Cambridge, UK), staining was detected using a peroxidase conjugated streptavidin complex (Dako) and colour developed using 3,3' Diaminobenzidine (DAB) substrate (Sigma).
Molecular analyses
Ankle joints were snap frozen in liquid nitrogen and homogenised in Qiagen RLT plus buffer (Qiagen, Crawley, UK) using Precellys24 ceramic bead homogenisation technology (Bertin Technologies, Montigny-le-Bretonneux, France). RNA was extracted using RNeasy Plus mini kit (Qiagen) and genomic DNA contamination eliminated with Turbo DNA-free kit (Applied Biosystems, Foster City, California, USA). Complementary DNA was synthesised using SuperScriptIII reverse transcriptase and OligoDt primers (Invitrogen). Quantitative real-time PCR was performed using QuantiTect primers (Qiagen) and ABI Prism 7900 sequence detector system (Applied Biosystems). RQ values were calculated using the 2 −( ΔΔ Ct) method and normalised to an individual naive AnxA1 +/+ or AnxA1 −/− mouse (calibrator sample).
All Ct values were normalised to endogenous Gapdh gene product. Since factors such as hypoxia can infl uence Gapdh gene levels, 28 a second house-keeping gene Rpl32 was used to normalise and confi rm data (see table S2 ).
Statistics
Data are expressed as mean±SE. Student t test was used to compare two groups. Comparison of clinical scores and paw volumes were made using 2-way analysis of variance. A value of p<0.05 was considered signifi cant.
RESULTS

Characterisation of joint inß ammation
We began this study to optimise the model by comparing two different protocols: 200 μl of serum at day 0 (as in 22 ) or 50+50 μl at day 0 and day 2. A remarkably similar arthritic response could be measured with respect to disease profi le and intensity (fi gure 1A). High levels of disease were achieved as early as day 2 postinjection with maximal response by day 6, after which the disease resolved to almost normal by day 20. Incidence of disease was similar between the two volumes of K/BxN serum (table S1). The arthritic response was mirrored by changes in paw volume with similar profi les with no difference between the two protocols (fi gure 1B).
Microscopic analyses of non-arthritic ankle joints showed an acellular articular cavity with intact unicellular synovial lining and uniform cartilage structure (fi gure 1C, top panel). In contrast, arthritic joints from both 50+50 μl and 200 μl K/BxN arthritis groups displayed marked cell infi ltration within a thickened synovial lining. Pannus invasion leading to cartilage erosion was observed and proteoglycan loss was confi rmed with safraninO (fi gure 1C, middle and bottom panels). Quantitative histological scoring showed no signifi cant difference between the two groups of arthritic mice (fi gure 1D).
The ankle is the predominant joint to be affected in this model of infl ammatory arthritis, yet we monitored structural changes in the knee, as is perhaps more relevant to human disease; we observed that knee joints displayed mild synovitis accompanied with thickening of synovial lining, pannus formation and marked cartilage erosion (see fi gure S1). Based on these results, in agreement with a recent published study, 29 the 50+50 μl serum protocol was selected for subsequent experimentation.
Expression of AnxA1 and FPR2 in the joint
At the mRNA level, a low degree of expression for both FPR1 and FPR2 could be measured, with high AnxA1 message content (see table S2 ). These results were partially confi rmed by protein analyses, since AnxA1 was mildly expressed and localised predominantly in the synovial lining, while FPR2 was localised to the periosteal lining with very little detection in synovium (fi gure 2A). In arthritic joints, AnxA1 and FPR2 expression was highly detectable within the synovial lining (FPR2) and tissue (AnxA1 and FPR2) (fi gure 2B). Antibody controls and AnxA1 −/− joints did not show any staining (fi gure 2C,D).
Dex is inactive in AnxA1 −/− mice
Despite wide application of this model of infl ammatory arthritis, the bioactions of glucocorticoids have been scantly investigated. We selected the 10-μg dose of Dex from initial studies (fi gure S2). Administration of Dex to AnxA1 +/+ mice exerted profound inhibitory effects with ~60% inhibition of the severity of arthritis at day 6 and ~80% at day 10 compared with vehicle-treated mice (fi gure 3A). AnxA1 −/− mice displayed a similar profi le of arthritis to AnxA1 +/+ animals. However, the antiarthritic effect of Dex was absent in animals nullifi ed for AnxA1 (fi gure 3A). Analysis of presence of severe disease (score ≥8) indicated a trend for higher incidence in AnxA1 −/− mice and a marked reliance on endogenous AnxA1 for the protective effects of Dex (table S3) .
Histological analyses were in line with arthritic scores. AnxA1 +/+ mice displayed marked synovitis accompanied by pannus formation and cartilage destruction (fi gure 3B, left panels). Treatment with Dex prevented signs of disease (fi gure 3B, middle panels), while AnxA1 −/− mice treated with vehicle control (not shown) and Dex (fi gure 3B, right panels) showed similar disease pathology to AnxA1 +/+ mice. These structural changes were refl ected in the histological scores with ~75% inhibition afforded by Dex only in AnxA1 +/+ mice (fi gure 3C). Analyses of infl ammatory gene messages, normalised to Gapdh and Rpl32 (see fi gure S3) and selected from our previous study, 22 revealed that in wild type mice Dex inhibited Cxcl10, Nos2, interleukin (IL)-1β and Ccl2. Tumour necrosis factor α (TNFα) was inhibited by ~25% while expression of the chemokine receptor Cxcr3 was not modulated (fi gure 3D). These inhibitory effects of Dex were absent or signifi cantly reduced in AnxA1 −/− mice.
Next, we monitored expression of AnxA1 and its receptors, normalised to Gapdh and Rpl32 (see fi gure S4). In arthritic AnxA1 +/+ mice, both FPR1 and FPR2 mRNA expression was enhanced over naive joints (fi gure 4), a fi nding which is in line with FPR2 protein expression (see fi gure 2). Dex decreased both FPR1 and FPR2 message with little comparative effect on AnxA1 (fi gure 4). In mice devoid of AnxA1, a >10-fold increase in FPR1 expression was observed comparing arthritic to naive joints, with FPR2 remaining at a similar expression. In absence of AnxA1, Dex could not regulate either FPR1 or FPR2 gene expression (fi gure 4).
SuperAnxA1 accelerates resolution of the arthritic joint
In the fi nal set of experiments, we assessed the pharmacological potential of these fi ndings. Proteinase 3 (PR3) may limit AnxA1 functions in neutrophilic infl ammation, cleaving it at the N-terminal region. Thus, we monitored the profi le of PR3 gene in the arthritic joint and found it signifi cantly rose from baseline (day 0) to peak of disease (day 6) (fi gure 5 and fi gure S5). This observation, coupled with abundant expression of FPR1 and FPR2 in the joints justifi ed the testing of SuperAnxA1. Dosed at 1 μg per mouse, AnxA1 was not particularly effective in reducing disease (fi gure 5B). On the other hand, cleavage-resistant SuperAnxA1 did not affect disease progress (eg, from day 2 to day 6) but signifi cantly accelerated resolution (fi gure 5B), with 50% less disease incidence compared with controls (table 1) .
The macroscopic joint protection afforded by SuperAnxA1 was confi rmed microscopically, with preservation of cartilage structure with little loss of proteoglycans (fi gure 5C, middle 
test). (D)
Quantitative real-time PCR was performed on cDNA from left ankle joints; pro-inß ammatory genes were analysed with all Ct values normalised to endogenous Gapdh (four mice per group). RQ values were calculated using 2−(ΔΔCt) and data shown here as mean % gene inhibition by Dex relative to vehicle control groups±SE. Naive joints were set as the calibrator samples. *p<0.05 versus respective vehicle control (Student t test). panels). Synovitis was apparent within these joints, but substantially lower than controls (fi gure 5C, top panels). The joints of AnxA1 treated mice were disrupted to a similar extent as controls (fi gure 5C, bottom panels). Quantitative analysis of damage within the ankle joints confi rmed the observational studies (fi gure 5D). Finally, ankle joints from vehicle-and SuperAnxA1-treated mice demonstrated reduced expression of the Cxcl10 and Cxcr3 pair, as well as Nos2, IL-1β, Ccl2, IL-6 but not IL-10 and TNFα (fi gure S6).
DISCUSSION
AnxA1 is the prototype of a new class of mediators able to potently modulate both the innate and adaptive immune response; while effecting inhibitory properties on infl ammatory cells, setting in motion pro-resolving responses, this protein acts as a positive relay in T cell activation. 4 As an example, exogenous and endogenous AnxA1 potentiate T cell receptor-downstream signalling 30 and assure proper dendritic cell-mediated T cell clonal expansion. 31 In agreement with these dual functions, AnxA1 −/− mice experience augmented acute infl ammatory responses, 14 15 yet display reduced degree of tissue damage in an experimental model of multiple sclerosis. 32 Less clear is the role of the protein in models of arthritis.
In the collagen-induced arthritis model, AnxA1 injection during the immune phase (within 1 week postcollagen immunisation) led to higher disease as emerged 3 weeks later. 30 In a model of antigen-induced arthritis, assessed at a single time-point (day 7), endogenous AnxA1 modulated some of the anti-infl ammatory effects of Dex, including inhibition of pro-infl ammatory genes including IL-1β and TNFα. 20 No studies have yet investigated the role of endogenous or exogenous AnxA1 in the seruminduced infl ammatory arthritis model. K/BxN serum-induced arthritis 33 34 is a versatile model that can be applied to transgenic mice with little dependence on strain. 35 This model addresses the contribution of neutrophils and macrophages to infl ammatory arthritis, as evident from depletion studies. 36 37 Conversely, this experimental arthritis does not rely on T and B cells as demonstrated with the RAG1 −/− mice 28 which, in contrast, display delayed disease onset and severity in collagen-induced arthritis. 38 Here we describe that low dosage arthritogenic serum provokes a high degree of arthritis and disease incidence, data which are in agreement with a recent study by Boilard's group. 29 We noted a remarkable joint disruption and report a novel parallelism between the ankle and knee joint. Marked synovitis associated with disruption of cartilage occurs along a well-defi ned time-profi le with peak disease at day 6 followed by a resolution phase. 22 35 Use of transgenic mice has allowed some defi nition of the disease pathogenesis, revealing a fundamental role for myeloid cells 36 37 and IL-1. 39 40 More recently, this model of arthritis has been applied to proresolving pathways, noting that 12/15-lipoxygenase or melanocortin type-3 receptor defi cient mice experience a higher degree of disease. 21 22 AnxA1 is highly abundant in myeloid and stromal cells and its expression can be modulated by glucocorticoids and other antiinfl ammatory drugs. 41 In addition, cell activation such as adhesion or extravasation also engages the AnxA1 system as a way to activate an inhibitory circuit to modulate the infl ammatory response. 27 After several pharmacological investigations with AnxA1 or mimetics, AnxA1 null mice were produced and tested in models of acute infl ammation 15 24 revealing important modulatory functions. 4 As discussed above, AnxA1 role in chronic infl ammatory settings in less defi ned.
This study began by detecting protein and mRNA of elements of the AnxA1 pathway during ongoing infl ammatory arthritis, reporting a high degree of expression for AnxA1, FPR1 and FPR2 both in resting and arthritic joints. At the protein level, AnxA1 localisation in the mouse synovium seems to parallel that observed in the human rheumatoid arthritis synovium. 42 However, at least in the conditions applied here, lack of AnxA1 does not seem to impact on the profi le of disease. Yet, it remains to be seen whether such a lack of function would also be seen in knockouts for the AnxA1 receptors. 5 43 As an example, in preliminary observations, mice nullifi ed for FPR2 displayed higher arthritic score upon injection of the arthritogenic serum. 44 Glucocorticoids have been scarcely tested in this model. Buttgereit et al have tested the effect of osteoblast-restricted absence of glucocorticoid signalling on disease outcome, noting a worsening with marked joint disruption. 23 In these mice, bone cells could not respond to glucocorticoids from birth; thus, it is possible that developmental aspects might be relevant and subtle long-term alterations occur. For instance, it is known that glucocorticoids exert a permissive effect on important cytokine function in the liver, by assuring proper expression of the IL-6 and IL-1 receptors. 45 46 IL-6 is also a master-cytokine for osteoblasts (and fi broblasts) and so a malfunctioning or inadequate glucocorticoid signalling, prolonged from birth, may generate responses that are not necessarily replicated by acute glucocorticoid treatment.
In keeping with this, our pharmacological analyses with doses of Dex as low as 10 μg exerted potent protective effects on the joint, evident both as inhibition of pannus formation and chondro-protection. It was striking to observe that the effects of the glucocorticoid were lost in AnxA1 −/− animals. Thus, while AnxA1 −/− mice did not experience a difference in the extent and profi le of arthritis, at variance from the antigen-induced arthritis model, 20 endogenous AnxA1 still proved important in the inhibitory effects of Dex on a discrete set of pro-infl ammatory genes, of which IL-1β, Cxcl10 and Ccl2 were of particular interest. Selective modulation of gene expression downstream AnxA1 is in keeping with the observations made in the antigen-induced Figure 4 ProÞ le of AnxA1, FPR1 and FPR2 gene product expression in ankle joints of AnxA1 +/+ and AnxA1 −/− mice treated with dexamethasone (Dex). AnxA1 +/+ and AnxA1 −/− mice were given an intraperitoneal injection of K/BxN serum (50 μl at day 0 and day 2) and then received vehicle or Dex (10 µg intraperitoneally daily). Quantitative real-time PCR was performed on cDNA from left ankle joints of mice from each experimental group (day 10). The AnxA1, FPR1 and FPR2 genes were analysed with all Ct values normalised to endogenous Gapdh (four mice per group). Naive joints were set as the calibrator samples. Mean RQ values±SE shown here were calculated using 2−(ΔΔCt) method. *p<0.05 versus naive; ¤p<0.05 versus appropriate vehicle control; #p<0.05 versus AnxA1 +/+ group (Student t test).
arthritis model. 20 The fundamental role that IL-1β exerts in this model of infl ammatory arthritis has been addressed through a variety of genetic approaches targeting directly the cytokine, its receptor 39 47 or endogenous antagonist. 40 Modulation of gene expression downstream of endogenous AnxA1 can also be discussed in relation to the modulation of genes of the AnxA1 pathway. In fact, Dex did not appear to induce AnxA1 or FPR gene expression at the level of the joint, yet was highly reliant on endogenous AnxA1 both with respect to cell recruitment and infl ammatory gene expression. We reason that these data indicate multiple functions of endogenous AnxA1, which become of relevance only after administration of the glucocorticoid.
The lack of correlation between AnxA1 gene product and protein is intriguing though it should be said that glucocorticoidregulation of the AnxA1 pathway is multifaceted; thus, nongenomic modulation 48 with release of the protein, for instance, could account for apparent lower tissue levels of the AnxA1 protein. AnxA1 analysis, at a single time point, could also be confounded by genomic regulation exerted by glucocorticoids 15 49 Data report the number of mice with a severe arthritic score taking a threshold of ≥8. SuperAnxA1 or AnxA1 was given from day 2 at daily doses of 1 µg intraperitoneally; the K/BxN arthritogenic serum was given on day 0 and day 2 at volumes of 50 µl each time. and other factors present in an infl amed joint such as IL-6 50 and TNF. 51 Clearly, the current lack of characterisation of the AnxA1 promoter contributes to this poor understanding of the mechanisms operative in these settings. Moreover, the fact that glucocorticoids like Dex induce AnxA1 gene in innate immune cells 14 15 while downregulating it in adaptive immune cells 52 adds another layer of complexity to this issue which inevitably requires further experimentation.
The versatility of this model of infl ammatory arthritis justifi es its application to a variety of targets; in line with the major infi ltration of neutrophils and mast cells, 53 we could observe dynamic expression of PR3 gene product in the arthritic joint. PR3 is emerging as an important effector of neutrophilic infl ammation 54 and can cleave, among a variety of substrates, also AnxA1. 55 Therefore, we concluded this study by testing the potential of AnxA1 mimetics, comparing the effect of native protein with that of SuperAnxA1, a mutant resistant to serine protease-induced cleavage. 26 Administered at the dose of 1 μg (corresponding to 27 pmol), SuperAnxA1, but not AnxA1, attenuated joint disease. It was interesting to note that SuperAnxA1 did not impact on the induction of arthritis yet it accelerated the resolution process so that by day 10 a preserved joint structure could be observed. We wish to propose that higher resistance to proteolysis might underlie its pharmacological effi cacy, though we cannot exclude the confounding element of potential differences in pharmacokinetics. In any case, these results provide strong proof-of-concept that an AnxA1 derivative, resistant to proteolysis, could be benefi cial in modulating joint infl ammation. SuperAnxA1 could be the backbone for future strategies aiming at capitalising AnxA1 biology for novel antiarthritic approaches.
Glucocorticoids are of wide clinical use because of their ability to impact several effectors of arthritis, with a recent appreciation that, besides inhibition of pro-infl ammatory gene expression, gene induction is also of therapeutic relevance. 56 57 In the context of chronic infl ammatory diseases, induction of dual-specifi city phosphatase 1 58 and glucocorticoid-induced leucine zipper 59 genes could be of mechanistic value. In addition, we show here that endogenous AnxA1 is also relevant to the antiarthritic effect of low-dose Dex, yet we cannot demonstrate induction of this gene at the level of the arthritic joint leading to our proposal that the protein is either modulated in a non-genomic fashion by this glucocorticoid 41 60 or the regulation occurs outside the site of the arthritic joint, an obvious site being the vasculature and the control of the egress of bloodborne neutrophils. 4 Analysis of AnxA1 expression in distant tissues (eg, blood) during ongoing arthritis and glucocorticoid treatment can shed light on this point, which has also been touched upon above in relation to lack of correlation between joint AnxA1 mRNA and protein expression.
Collectively, this study reveals potent antiarthritic properties for Dex in a model of infl ammatory arthritis, using very low doses perhaps reminiscent of clinical application on low-dose glucocorticoids in RA 61 and, in terms of drug discovery programmes, justifi es the testing of AnxA1 mimetics to control the active phase of the disease.
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